Fintel reports that on March 4, 2025, Leerink Partners downgraded their outlook for Lexicon Pharmaceuticals (NasdaqGS:LXRX) ...

Adagene Inc. (“Adagene”) (Nasdaq: ADAG), a company transforming the discovery and development of novel antibody-based ...

Phase 2b vitiligo top-line results expected in mid-2025VYN202 Phase 1b psoriasis trial initiated with results anticipated ...

SLN (“Silence” or the “Company”), a global clinical-stage company developing novel siRNA (short interfering RNA) the ...

We recently published an article titled These 10 Stocks Defied Tuesday’s Bloodbath. In this article, we are going to take a ...

In a report released yesterday, Ben Hendrix from RBC Capital maintained a Hold rating on Walgreens Boots Alliance (WBA – Research Report), with ...

Qure (NASDAQ:QURE – Get Free Report)‘s stock had its “buy” rating reaffirmed by HC Wainwright in a research note issued on Tuesday,Benzinga reports. They presently have a $70.00 price target on the ...

China imposed an import ban on Illumina’s gene sequencers in response to President Trump’s escalating tariffs and trade war ...

Equities researchers at Leerink Partnrs dropped their Q1 2025 earnings per share (EPS) estimates for shares of Edgewise ...

Active leads BNP Paribas, Citigroup, JP Morgan, Bank of America, Morgan Stanley and Rabobank set IPTs for the two, three, five, seven, 10, 20, 30 and 40-year tranches at Treasuries plus 75bp area, ...

In this week’s InnovationRx newsletter, tariffs could hit medical devices, a gene therapy company that helps blind kids see ...

Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm: CANTA) today announced that Damian Marron, Interim CEO, will participate at the H.C.